Millennium Biotechnologies Receives $487,690 Purchase Order From Greek Distributor Nutrimedica, S.A.

Increasing Demand and the Introduction of the Ready-to-Drink Products in Greece Results in the Largest International Purchase Order Which More Than Doubles the Revenue Earned From Greece in the Entire Year of 2008


BASKING RIDGE, N.J., Jan. 8, 2009 (GLOBE NEWSWIRE) -- Millennium Biotechnologies Group, Inc. (OTCBB:MBTG), a leader in the development of targeted nutritional products in the Clinical Nutrition Market and Sports Nutrition Market, announces that it has received the largest international purchase order in Company history from Nutrimedica, S.A., an international nutritional supplement distributor, headquartered in Athens, Greece. The $487,690 purchase order will be produced and shipped to Greece during the first quarter of 2009.

The order from Nutrimedica, S.A. is the Company's largest international order and encompasses the complete medical line which includes 5 separate Resurgex(r) product lines and 12 SKUs of the Company's powdered and to Ready-To-Drink formulations. The Purchase Order is 104% greater than the total revenue the Company received from Greece in 2008. Nutrimedica, S.A. has been distributing Resurgex(r) products in Greece since March of 2006. Over a three year time period, the Company and Nurtrimedica, S.A. have been able to establish a strong international relationship in manufacturing and distributing elite, targeted nutritional supplements to the medical markets in Greece.

According to Chief Executive Officer Mark Mirken, "The strong broad-based demand for the Resurgex product line in Greece supports and encourages our expectation that the product line will be successful in the international marketplace as a whole. We plan to add additional international distributors of similar size this year. Importantly, Nutrimedica has been successful in broadening the usage of the Resurgex product line beyond Oncology, into other hospital settings including Intensive Care Units and Surgery Clinics as well as the retail marketplace in Greece."

About Millennium

Millennium's six marketed products form an advanced line of nutritional formulas. Resurgex Select(r) is a whole foods-based, calorically dense, high-protein nutritional formula developed for cancer patients undergoing chemotherapy or radiation treatments. Resurgex(r) and Resurgex Plus(r) are specialized, anabolic nutritional supplements rich in antioxidants that provide nutritional support post-treatment. Millennium also created Surgex(tm) sports nutrition formula to address the nutritional concerns of professional, Olympic, and amateur elite athletes. These athletes often experience similar symptoms post-workout to those battling immuno-compromised conditions, such as fatigue, loss of lean muscle, oxidative stress, and reduced immune function. Resurgex Essential(tm) and Resurgex Essential Plus(tm) are comprehensive, calorically dense formulas that meet and succeed the nutritional requirements of the assisted living community.

Statements in this news release regarding future financial and operating results, future growth in R&D programs, potential applications of the Millennium's technology, opportunities for the Millennium, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words 'will,' 'believes,' 'plans,' 'anticipates,' 'expects,' 'estimates,' and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of Millennium's intellectual property, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in Millennium's periodic reports, including Forms 10-KSB, 10-QSB, 8-K, and other forms filed with the Securities and Exchange Commission ('SEC').


            

Contact Data